Objectives: Circulating endothelial progenitor cells (EPC) are markers of vascular injury and their numbers decrease in acute stroke. However, the relation of EPC levels to stroke severity has not been quantified. MRI measurements of lesion volume provide an objective method for stroke severity assessment and outcome prediction. This cross-sectional study aims to determine whether EPC are correlated with lesion volume at baseline, lesion growth, and final lesion volume.
this study was to establish the associations between circulating EPC numbers and baseline lesion, lesion growth, and infarct volumes.
METHODS Study population. This is a prospective pilot study of patients with imaging-confirmed acute stroke admitted to the NIH Stroke Center at Washington Hospital Center (WHC) between October 2008 and May 2009. The study population consisted of 323 patients referred upon suspicion of an acute cerebrovascular event. Forty (12%) of these patients were diagnosed with hemorrhagic stroke, 13 (4%) with TIA, 96 (30%) with stroke mimics, and 175 (54%) had imaging-confirmed ischemic stroke. Forty-one (23%) of the admitted ischemic stroke patients participated in the natural history protocol. From this subgroup, patients with contraindications to MRI, known hematologic, renal, hepatic, or infectious disease, or active malignancy were excluded. The study population included 17 patients (10% of all ischemic stroke patients) and did not differ from the stroke cohort admitted to the hospital; however, the percentage of patients receiving recombinant tissue plasminogen activator was higher in the study group (table 1) .
Standard protocol approvals, registration, and patient consent. The protocol was approved by the NIH and WHC ethics committee. Written informed consent was obtained from all patients participating in the study.
Brain MRI and lesion volume measurements. MRI was
performed using a 3T (Philips Medical Systems) clinical scanner. 8 Baseline DWI (baseline lesion volume) and MTT (mean transit time) were performed 9 Ϯ 8 hours after last seen normal (LSN). Day 1 DWI and MTT were performed 37 Ϯ 19 hours and fluid-attenuated inversion recovery (FLAIR) (final lesion volume) was performed at 10 Ϯ 13 days after LSN. Lesion volumes were measured from DWI, MTT, and FLAIR series. 9 Growth of lesion volume was calculated as a difference between final FLAIR and baseline DWI lesion volumes. Baseline DWI lesion volume was 17 (3-42) and MTT was 32 (4 -136) mL (medians and first and third quartile). Day 1 DWI lesion volume was 20 (5-46) and MTT 32 (0.02-111) mL. FLAIR was 27 (4 -76) mL, and lesion growth volume was 9 (1-39) mL.
Blood collection. Peripheral blood was collected at 31 Ϯ 13 (day 1, n ϭ 17) and 76 Ϯ 29 hours (day 3, n ϭ 9) after LSN. Samples were centrifuged at 2,000 ϫg at 25°C for 25 minutes, and the isolated mononuclear cells were stored in autologous serum at Ϫ80°C until analysis. 10 The expression of cell surface antigens was determined by 4-color immunofluorescence staining. Briefly, 2 ϫ 10 6 cells were incubated in 120 L buffered saline containing 2% BSA with 20 L Fc-blocking agent (Miltenyi Biotech) for 10 minutes at 25°C. Thereafter, the cells were incubated at 4°C for 30 minutes with 20 L CD133/AC133-PE (Miltenyi Biotech), 20 L VEGFR2-FITC (R&D Systems), and 20 L CD34-ECD (Beckman Coulter) in a total volume of 200 L. The cells were washed twice before resuspension in 400 L stain buffer (BD Biosciences). Just prior to analysis on a FACS Vantage SE (BD Biosciences), DAPI nuclear dye was added to the cell suspension to allow for viability gating that was constantly 70 Ϯ 3%, across the 2 collection timepoints for all patients. A minimum of 1 ϫ 10 6 live cells were collected, and FACS analysis was performed in triplicate for each sample. Medians of 3 measurements were RESULTS EPC subsets in the stroke population were quantified at day 1, as follows: 0.02% (0.01-0.04) CD133ϩCD34ϩ, 0.01% (0.001-0.02) CD133ϩ VEGFR2ϩ, 0.002% (0.0006 -0.004) CD34ϩ VEGFR2ϩ, and 0.0009% (0.0003-0.0018) CD34ϩ CD133ϩVEGFR2ϩ (medians and first and third quartile). EPC measurements were also taken on day 3, and because no differences were observed between day 1 and 3 measurements, we used day 1 measurements for our calculations.
No differences in EPC regarding gender, ethnicity, or Rankin scale of the stoke population were found. The patients with previous stroke had increased CD34ϩVEGFR2ϩ ( p ϭ 0.03) and CD34ϩCD133ϩVEGFR2ϩ ( p ϭ 0.02) EPC subsets. Patients with nonactive cancer had increased subset CD133ϩCD34ϩ ( p ϭ 0.03). Neither influence of other cardiovascular risk factors on EPC levels nor differences in EPC among the stroke subtypes were found. Patients on ␤-blockers at admission had increased numbers of CD133ϩVEGFR2ϩ ( p ϭ 0.02) and CD34ϩVEGFR2ϩ ( p ϭ 0.04) subsets; however, no other treatment was associated with EPC changes.
DWI lesion volumes at baseline were smaller in patients with higher numbers of CD133ϩ CD34ϩ, CD133ϩVEGFR2ϩ, and CD34ϩ CD133ϩVEGFR2ϩ. DWI lesion volumes at day 1 were smaller in patients with higher CD133ϩCD34ϩ subset. Final lesion volume (FLAIR) was larger in male stroke patients with low CD34ϩVEGFR2ϩ levels. Lesion growth volume was increased in patients with low CD133ϩVEGFR2ϩ (table 2) . However, no association between age, NIH Stroke Scale score (NIHSS), modified Rankin scale, systolic blood pressure, diastolic blood pressure (DBP), white blood cells (WBC), red blood cells, hemoglobin (Hb), hematocrit, glucose, platelets, international normalized ratio (INR), and MTT volumes and EPC subsets was found.
After adjustment for factors influencing EPC (age and admission glucose), the levels of CD133ϩCD34ϩ and CD133ϩVEGFR2ϩ remained the most significant predictors of lesion volume at baseline, while the number of CD133ϩ CD34ϩ was the best predictor of day 1 lesion volume (table 3, model 1). Adjustment for mean arterial pressure and admission WBC showed that the Table 3 Standardized coefficient and significance for EPC subsets from the mononuclear fraction of peripheral blood and lesion and lesion growth volume, adjusted for age and admission glucose (model 1), for WBC and mean arterial pressure (model 2), and for hematocrit and INR (model 3) in the acute stroke patients a Spearman rank correlation between endothelial progenitor cells subsets from the mononuclear fraction of peripheral blood and acute lesion volume (baseline and day 1 DWI), final lesion volume (FLAIR), and lesion growth volume in the acute stroke patients CD133ϩVEGFR2ϩ subset was a significant predictor of the baseline lesion volume (table 3, model 2). INR and hematocrit adjustments revealed CD133ϩ VEGFR2ϩ cells as a significant predictor of lesion volume growth (table 3, model 3) . After adjustment for NIHSS, EPC subset levels were no longer predictive of lesion volumes.
DISCUSSION
This pilot study provides novel data regarding the link between EPC subsets and quantitative MRI measurements of lesion volume and lesion growth volume, which serve as surrogate markers of stroke severity. 6, 7 Acute ischemic stroke is associated with decreased EPC, 4 while an increase of EPC relates to a good outcome. 5 Accordingly, our study revealed that low EPC numbers indicate large lesion volumes, and higher EPC levels are linked with small ischemic lesions and smaller lesion growth. Despite the presence of various risk factors, comorbidities, and medications that could influence EPC levels in the stroke patients, higher EPC numbers were prognostic of smaller acute lesion volume, infarct volume, and lesion growth volume in acute stroke. After adjustments for major factors influencing EPC, the EPC levels remained predictive of lesion and lesion growth volume.
There were no differences in EPC levels between cardioembolic and large artery strokes. Increased EPC production influenced by estrogens in female patients may explain why the correlation between final lesion volume and EPC levels was significant only for male patients.
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